Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AMPENASDAQ:CALANASDAQ:CMRANASDAQ:PXMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPEAmpio Pharmaceuticals$0.00$0.00$0.00▼$0.45$3K3.9435 shs6 shsCALACalithera Biosciences$0.00$0.00$0.00▼$0.12$3K-2.3818,694 shs67 shsCMRAComera Life Sciences$0.00$0.00▼$0.03$3K0.7710,614 shsN/APXMDPaxMedica$0.00$0.00$0.00▼$0.39$1K-1.3213,787 shs342 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPEAmpio Pharmaceuticals0.00%0.00%+42.86%+42.86%-98.76%CALACalithera Biosciences0.00%0.00%-88.00%0.00%-97.00%CMRAComera Life Sciences0.00%0.00%-50.00%-50.00%-99.66%PXMDPaxMedica0.00%0.00%0.00%0.00%-99.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMPEAmpio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACMRAComera Life SciencesN/AN/AN/AN/AN/AN/AN/AN/APXMDPaxMedicaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPEAmpio Pharmaceuticals 0.00N/AN/AN/ACALACalithera Biosciences 0.00N/AN/AN/ACMRAComera Life Sciences 0.00N/AN/AN/APXMDPaxMedica 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPEAmpio PharmaceuticalsN/AN/AN/AN/A$4.04 per shareN/ACALACalithera BiosciencesN/AN/AN/AN/AN/AN/ACMRAComera Life Sciences$1.00M0.00N/AN/AN/ANaNPXMDPaxMedicaN/AN/AN/AN/A$0.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPEAmpio Pharmaceuticals-$8.63M-$11.01N/A∞N/AN/AN/AN/AN/ACALACalithera Biosciences-$39.65MN/A0.00∞N/AN/AN/AN/AN/ACMRAComera Life Sciences-$18MN/A0.00N/AN/AN/AN/AN/AN/APXMDPaxMedica-$18.29MN/A0.00∞N/AN/A-3,167.89%-560.35%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPEAmpio PharmaceuticalsN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/ACMRAComera Life SciencesN/AN/AN/AN/AN/APXMDPaxMedicaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPEAmpio PharmaceuticalsN/AN/AN/ACALACalithera BiosciencesN/AN/AN/ACMRAComera Life SciencesN/AN/AN/APXMDPaxMedicaN/A0.380.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPEAmpio Pharmaceuticals5.73%CALACalithera BiosciencesN/ACMRAComera Life SciencesN/APXMDPaxMedica4.90%Insider OwnershipCompanyInsider OwnershipAMPEAmpio Pharmaceuticals3.30%CALACalithera Biosciences6.60%CMRAComera Life Sciences8.90%PXMDPaxMedica1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPEAmpio Pharmaceuticals201.14 million1.10 millionNo DataCALACalithera Biosciences604.87 million4.55 millionNot OptionableCMRAComera Life Sciences230.74 million28.00 millionNot OptionablePXMDPaxMedica211.31 million11.20 millionNot OptionablePXMD, AMPE, CALA, and CMRA HeadlinesRecent News About These CompaniesPaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other ConditionsJanuary 14, 2025 | accesswire.comStudy Links Iron Deficiency to Disturbed Sleep Among Autism, ADHD PatientsSeptember 23, 2024 | msn.comBioMedNewsBreaks — PaxMedica Inc. (PXMD) Announces Immediate Exercise of Warrants to Total Approximately $884KSeptember 3, 2024 | msn.comPaxMedica Secures Immediate Exercise of WarrantsSeptember 3, 2024 | accesswire.comYale Study Unravels Autism, Brain Growth PatternsSeptember 1, 2024 | msn.comPaxMedica, Inc.: PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness InfectionAugust 27, 2024 | finanznachrichten.dePaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness InfectionAugust 27, 2024 | accesswire.comPaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101May 15, 2024 | globenewswire.comPXMD Stock Earnings: PaxMedica Misses EPS for Q1 2024May 14, 2024 | investorplace.comPaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory StrategyMay 7, 2024 | markets.businessinsider.comPaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory StrategyMay 7, 2024 | finance.yahoo.comPaxMedica (NASDAQ: PXMD) Announces PAX-101 Batch Completion for NDA Application to FDAMay 3, 2024 | theglobeandmail.comPaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell PodcastApril 26, 2024 | finance.yahoo.comUrgent Action: PaxMedica (NASDAQ: PXMD) Addresses Medical Crisis in MalawiApril 25, 2024 | theglobeandmail.comPaxMedica (NASDAQ: PXMD) Completes Key Step in Preparation of PAX-101 for NDA Submission to FDAApril 25, 2024 | theglobeandmail.comPaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101April 23, 2024 | globenewswire.comPaxMedica, Inc.: PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping SicknessApril 18, 2024 | finanznachrichten.deChoosing Unknown Penny Stocks, 3 Top TipsApril 15, 2024 | pennystocks.comPaxMedica, Inc.: PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA SubmissionApril 12, 2024 | finanznachrichten.deNasdaq Down 300 Points; BlackRock Posts Upbeat EarningsApril 12, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumNVIDIA Stock Surges on Bullish News: How High Could It Climb?By Thomas Hughes | May 13, 2025View NVIDIA Stock Surges on Bullish News: How High Could It Climb?Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains?By Chris Markoch | April 26, 2025View Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains?PXMD, AMPE, CALA, and CMRA Company DescriptionsAmpio Pharmaceuticals NYSE:AMPE$0.0030 0.00 (0.00%) As of 05/23/2025Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.Calithera Biosciences NASDAQ:CALA$0.0006 0.00 (0.00%) As of 05/23/2025Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Comera Life Sciences NASDAQ:CMRAComera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.PaxMedica NASDAQ:PXMD$0.0001 0.00 (0.00%) As of 05/23/2025 03:26 PM EasternPaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
